![]() |
Name |
cladamide
|
Molecular Formula | C42H85NO5 | |
IUPAC Name* |
2-hydroxy-N-(1,3,4-trihydroxyoctacosan-2-yl)tetradecanamide
|
|
SMILES |
CCCCCCCCCCCCCCCCCCCCCCCCC(O)C(O)C(CO)NC(=O)C(O)CCCCCCCCCCCC
|
|
InChI |
InChI=1S/C42H85NO5/c1-3-5-7-9-11-13-15-16-17-18-19-20-21-22-23-24-25-26-28-29-31-33-35-39(45)41(47)38(37-44)43-42(48)40(46)36-34-32-30-27-14-12-10-8-6-4-2/h38-41,44-47H,3-37H2,1-2H3,(H,43,48)/t38-,39+,40+,41-/m0/s1
|
|
InChIKey |
JFQXGMIAKMWZEK-QLLOZFISSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 684.14 | ALogp: | 10.8 |
HBD: | 5 | HBA: | 5 |
Rotatable Bonds: | 39 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 110.0 | Aromatic Rings: | 0 |
Heavy Atoms: | 48 | QED Weighted: | 0.034 |
Caco-2 Permeability: | -5.478 | MDCK Permeability: | 0.00000194 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.063 |
Human Intestinal Absorption (HIA): | 0.129 | 20% Bioavailability (F20%): | 0.522 |
30% Bioavailability (F30%): | 0.999 |
Blood-Brain-Barrier Penetration (BBB): | 0.001 | Plasma Protein Binding (PPB): | 100.84% |
Volume Distribution (VD): | 0.762 | Fu: | 0.88% |
CYP1A2-inhibitor: | 0.019 | CYP1A2-substrate: | 0.125 |
CYP2C19-inhibitor: | 0.084 | CYP2C19-substrate: | 0.035 |
CYP2C9-inhibitor: | 0.026 | CYP2C9-substrate: | 0.995 |
CYP2D6-inhibitor: | 0.07 | CYP2D6-substrate: | 0.011 |
CYP3A4-inhibitor: | 0.157 | CYP3A4-substrate: | 0.005 |
Clearance (CL): | 3.932 | Half-life (T1/2): | 0.039 |
hERG Blockers: | 0.846 | Human Hepatotoxicity (H-HT): | 0.01 |
Drug-inuced Liver Injury (DILI): | 0.023 | AMES Toxicity: | 0.019 |
Rat Oral Acute Toxicity: | 0.004 | Maximum Recommended Daily Dose: | 0.006 |
Skin Sensitization: | 0.96 | Carcinogencity: | 0.005 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.02 |
Respiratory Toxicity: | 0.682 |